GENB

Generate Biomedicines, Inc.

Fundamental data last updated:October 1, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Financial Services

industry

Asset Management

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.

 


Analyze GENB on TradingView

VALUATION

P/E

-3.23

Market Cap ($M USD)

$1.68B

Forward P/E

-5.35

PEG

-0.13

PRICE TO SALES

52.61

PRICE TO BOOK

-1.06

EV / EBITDA

-7.79

5-Year Average P/E

Free Cash Flow Yield

-12.16%

DCF Value

$-70.87

Graham Number

N/A

Price to FCF

-8.22

EV to FCF

-7.96

Earnings Yield

-30.98%

FCF Yield

-12.16%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$4.06

Next Year EPS Growth Estimate

-$2.45

Next Year Revenue Growth Estimate

$163.20M

Return on Equity (ROE)

38.68%

FREE CASH FLOW

Operating Margin

-737.04%

Debt-to-Equity

-0.11

Piotroski F-Score

N/A

Altman Z-Score

N/A

Return on Invested Capital (ROIC)

-94.79%

Current Ratio

2.85

Quick Ratio

2.85

Net Debt to EBITDA

0.25

Interest Coverage

-206.92

Gross Profit margin

100.00%

FCF PER SHARE

$-4.08

REVENUE PER SHARE

$0.64

Analyze GENB on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be pricing GENB Generate Biomedicines, Inc. with a heavy dose of skepticism. With a DCF value deeply negative and a Forward P/E also in the red, the stock appears to be mispriced relative to its intrinsic value. The negative Earnings Yield and lack of an Altman Z-score suggest significant financial instability and potential growth challenges. Despite a “Buy” consensus rating, the financial health of this company raises red flags, especially when considering its negative ROIC and operating margins. Investors should tread carefully, as the valuation metrics paint a picture of a company struggling to find its footing.

AI Exposure / Tech Reliance

Operating within the asset management sector, GENB is positioned to leverage AI and tech advancements to optimize portfolio management and client interactions. However, the industry's traditional nature may slow down rapid tech adoption. Their ability to integrate AI could be pivotal in maintaining competitiveness and enhancing operational efficiency.

The Bull Case

For the optimistic investor, GENB's Return on Equity of 38.68% stands out as a beacon of potential. This suggests that the company is generating substantial returns on shareholder investments, indicating strong capital efficiency. The current ratio of 2.85 also points to solid liquidity, providing a cushion against short-term liabilities. Despite the lack of a Piotroski F-Score, the company's ability to maintain a positive ROE amidst challenging metrics could be seen as a testament to its underlying resilience.

The Bear Case

GENB's structural weaknesses are glaring, with a Price/Sales ratio of 54.59 and a Price/Book ratio in the negative territory, signaling severe overvaluation. The company's negative cash flow metrics, such as the FCF Yield and Price to FCF, highlight a troubling inability to generate cash. With an operating margin of -737.04%, profitability is a distant dream, and the stock's proximity to its 52-week high suggests technical overextension. These factors collectively paint a picture of a company fraught with financial instability and valuation risks.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$23.50

Institutional Ownership %

1-Year Beta

0.00

Insider Buying % (6 Mo)

Distance to 52-Week High

27.96%

Distance to 52-Week Low

15.97%

EARNINGS SURPRISE %

N/A

50-DAY SMA

$13.06

200-DAY SMA

$12.90

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.